MJNA Medical Marijuana Inc

Medical Marijuana, Inc. CEO Featured in Reuters Highlighting Recent M&A Shifts in the Cannabis Industry

Medical Marijuana, Inc. CEO Featured in Reuters Highlighting Recent M&A Shifts in the Cannabis Industry

SAN DIEGO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --  (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that the Company's CEO Dr. Stuart Titus was featured in global financial news outlet Reuters discussing the current landscape of mergers and acquisitions (M&A) within the cannabis industry.

The August 11, 2020, Reuters article entitled “,” provided coverage on what’s next for public cannabis companies as they celebrate their collective growth during the COVID-19 pandemic. Though there is a tremendous amount of financial success to be celebrated, the article explains that for some it may be another few months before M&A activities reconvene and Dr. Titus is quoted as saying, “It could be another quarter before Canadian companies start making deals as they are still cleaning up their balance sheets.”

According to the article, cannabis retailers in the U.S. may be quicker to begin making deals because many people are hopeful that the presidential election in November will lead to the federal legalization of cannabis. Still, as the article points out, funding sources will be more cautious about how they spend. 

“We are currently focused on developing strategic sales strategies in hopes to keep our firm profitable and we are always on the lookout for new opportunities to expand our portfolio,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. 

The article was picked up by several leading global news outlets, including:

  • , and 

As a result of Dr. Titus’ work with national regulatory bodies, including the US FDA last year, he has helped legalize the use and import of cannabidiol (CBD) into several Latin American countries and has expanded access to CBD around the world.

About Medical Marijuana, Inc.

. Medical Marijuana, Inc. () is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by  and ; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including and. Medical Marijuana, Inc. was named a top CBD producer by . Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company's flagship product  has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.

Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at  or by visiting . To see Medical Marijuana, Inc.'s corporate video, .

Shareholders and consumers are also encouraged to 

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

LEGAL DISCLOSURE

Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:

Public Relations Contact:

Andrew Hard

Chief Executive Officer

CMW Media

P. 858-264-6600



Investor Relations Contact:

P. (858) 283-4016

EN
18/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medical Marijuana Inc

 PRESS RELEASE

Medical Marijuana, Inc. Appoints New CEO; Highlights Renewed Focus on ...

Medical Marijuana, Inc. Appoints New CEO; Highlights Renewed Focus on Profitability, Further Expansion World’s First-Ever Publicly Traded Cannabis Company Appoints Longtime Board Member as New CEO SAN DIEGO, CA , March 14, 2023 (GLOBE NEWSWIRE) -- via – (OTC: MJNA) (the “Company”), a holding company with operating assets dedicated to the cannabis and hemp industries, along with portfolio investments in companies in the biotechnology industry, announced today the appointment of Dr. Timothy R. Scott as its new Chief Executive Officer, President, and Chairman of the Board. Dr. Scott takes ...

 PRESS RELEASE

Medical Marijuana, Inc. Participates in Preclinical Research Study on ...

Medical Marijuana, Inc. Participates in Preclinical Research Study on Therapeutic Benefits of CBD on Traumatic Brain Injuries Study Carried Out by Center for Research and Advanced Studies of the IPN and the Siglo XXI National Medical Center Show Advantages of Oral Administration of CBD to Reduce Levels of Neuronal Death in Animal Model SAN DIEGO, CA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- via –  (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply c...

 PRESS RELEASE

Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Launches Two New F...

Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Launches Two New Full Spectrum Concentrations in Brazil With Competitive Price Point New Products Offer 3,000mg to 6,000mg, Will Come in Jars of 30 and 60mL, Presenting Significant Cost Savings to Rapidly Growing Brazil Market SAN DIEGO, CA, Jan. 24, 2023 (GLOBE NEWSWIRE) -- via – (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary launched two new fu...

 PRESS RELEASE

Medical Marijuana, Inc. Subsidiary Kannaway Expands Leadership Team Wi...

Medical Marijuana, Inc. Subsidiary Kannaway Expands Leadership Team With Appointment of Industry Veterans to Roles of Executive Vice President and Vice President of Information Technology Direct Selling Subsidiary Taps Network Marketing Legends to Lead Communication and Information Technologies as Company Continues International Expansion SAN DIEGO, CA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via – (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply ch...

 PRESS RELEASE

Medical Marijuana, Inc. Reports $4.9 Million in Net Revenue in 2022 Th...

Medical Marijuana, Inc. Reports $4.9 Million in Net Revenue in 2022 Third Quarter Financial and Operational Results SAN DIEGO, CA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via – (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today its financial results for the quarter ending September 30, 2022, and provided an overview of recent operational highlights. First Quarter 2022 Financial and Operational Highlights Generated $4.9 million...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch